STOCK TITAN

Hillstream BioPharma, Inc. - $hils STOCK NEWS

Welcome to our dedicated page for Hillstream BioPharma news (Ticker: $hils), a resource for investors and traders seeking the latest updates and insights on Hillstream BioPharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hillstream BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hillstream BioPharma's position in the market.

Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company, has signed an exclusive worldwide licensing agreement with Avior Inc. to develop and commercialize TH104, a clinical-stage asset for the treatment of chronic pruritis. TH104 has a dual mechanism of action and is intended to be used for the treatment of moderate-to-severe cholestatic pruritis in patients with primary biliary cholangitis. Tharimmune expects to complete a phase 2 clinical trial in approximately 12 months after aligning with FDA on trial design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
61.49%
Tags
none
-
Rhea-AI Summary
Hillstream BioPharma changes name to Tharimmune, Inc. and will trade under ticker symbol THAR on September 25, 2023. Company progressing towards acquiring clinical stage asset TH104 and expects to complete phase 1 trial by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
-
Rhea-AI Summary
Hillstream BioPharma announces exclusive option agreement to acquire AV104, a clinical stage asset for the treatment of chronic pruritis. Anticipates completion of Phase 1 & Phase 2 clinical trials in approximately 12 months. Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis. AV104 has expansion opportunities in treating other liver-related and non-liver related diseases. CEO states transformational change for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.44%
Tags
Rhea-AI Summary
Hillstream BioPharma to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
conferences
-
Rhea-AI Summary
HSB- Hillstream BioPharma, Inc. announces collaboration with Minotaur Therapeutics, Inc. and OmniAb, Inc. to develop next-generation targeted Knob biologics (PicobodiesTM) against HER3 and a new undisclosed oncology target, extending partnership to include validated targets. HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors, plans to file an IND in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Summary
Hillstream BioPharma has signed an exclusive agreement with Applied Biomedical Science Institute to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The goal is to develop proprietary multi-format biologics, including bi-specific antibodies and antibody drug conjugates (ADCs), to combat drug-resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer, and ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
Hillstream BioPharma, Inc.

Nasdaq:HILS

HILS Rankings

HILS Stock Data

4.17M
11.46M
38.91%
0.89%
0.3%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services